Toregem Biopharma Secures $5.3M to Accelerate Human Tooth Regeneration Trials

Japanese pharmaceutical company Toregem Biopharma has secured approximately USD 5.3 million (equivalent to Rp 85 billion) in its latest funding round. These funds are designated to accelerate human clinical trials for tooth regeneration, a breakthrough that could allow new teeth to grow to replace damaged ones.

The technology originated in 2023 when Toregem discovered a method to inhibit the gene responsible for suppressing tooth growth. This approach seeks to move beyond the use of dentures or implants, potentially allowing patients to regrow live teeth from their own tissue.

Toregem President Honoka Kiso stated that the company’s ultimate goal is to offer a scientific and advanced clinical solution for tooth growth derived from the patient’s own tissue. This vision is shared by founder and lead researcher Katsu Takahashi, who described the idea of growing new teeth as a dream for every dentist.

The Science of Tooth Regeneration

A 2021 study conducted by Toregem demonstrated that artificial neutralizing antibodies could suppress a protein called USAG-1. This specific protein is known to act as an inhibitor for the growth of tooth buds.

The research showed positive results in animals, specifically mice born without teeth due to a deficiency in the Runx2 gene, which serves as the master switch for bone and tooth development. These mice were successfully able to regrow teeth following the treatment.

Progress Toward Human Application

Following the animal studies, a 2024 study concluded that a similar approach could potentially work in humans. Phase 1 clinical trials, which involved adult male participants, were conducted last year to test the safety of the method.

While the safety trials have been completed, the final results are currently awaiting publication. With the new funding, Toregem plans to launch Phase 2 clinical trials involving human participants in Japan.

Potential Challenges and Skepticism

Despite the promise, some experts have expressed doubt regarding the drug’s effectiveness in adults. Mary MacDougall, dean of the faculty of dentistry at the University of British Columbia, shared concerns with New Scientist last year regarding the role of dental epithelial cells.

MacDougall suggested that the therapy might only be effective for children who still possess a high volume of these fundamental cells. She argued that adults who have lost teeth generally lack these cells, which could mean they may not benefit from the treatment.

MacDougall raised concerns about the precision of the drug. She noted that directing the medication to work on one specific tooth could be difficult, creating a risk where tooth growth could occur uncontrollably in multiple locations simultaneously.

The Path to Commercialization

Toregem has set an ambitious target to bring this therapy to market by 2030. However, the company has not yet released a specific schedule for when the next stages of trials will begin.

The road to commercialization involves several hurdles, including the biological differences between mice and humans. The company must find ways to reduce the cost of producing neutralizing antibodies on a large scale without compromising safety or quality.

If Phase 2 trials prove successful, the next steps may include trials with larger populations and a review by regulators in Japan and other countries. This regulatory process typically takes several years before a product can be granted a distribution permit.

While this technology is still in early development, it reflects a broader trend in biotechnology aimed at regenerating human tissues, including skin, bone, and internal organs. If successful, it could offer a more natural biological alternative to current high-cost implants and long recovery periods.

Frequently Asked Questions

What is the role of the USAG-1 protein in this treatment?

USAG-1 is a protein that inhibits the growth of tooth buds. Toregem’s treatment uses artificial neutralizing antibodies to suppress this protein, thereby allowing tooth growth to occur.

When is the therapy expected to be available to the public?

Toregem Biopharma has set a target for the therapy to be marketed by the year 2030, though it is still undergoing clinical trials.

What are the primary concerns regarding the treatment for adults?

Some experts, including Mary MacDougall, suggest that adults may lack the necessary dental epithelial cells required for the treatment to work, and there are concerns that tooth growth could occur in an uncontrolled manner.

Do you believe biological tooth regeneration will eventually replace traditional dental implants?